Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer

被引：2
|
作者：
El Melegy, N. T. [1 ]
Aboulella, H. A. [2 ]
Abul-Fadl, A. M. [1 ]
Mohamed, N. A. [1 ]
机构：
[1] Assiut Univ, Fac Med, Dept Biochem, Assiut, Egypt
[2] Assiut Univ, Fac Med, Dept Urol, Assiut, Egypt
来源：
BRITISH JOURNAL OF BIOMEDICAL SCIENCE | 2010年 / 67卷 / 03期
关键词：
N-Acetylneuraminic acid; Prostate-specific antigen; Prostatic hyperplasia; Prostatic neoplasms; SERUM SIALIC-ACID; CATHEPSIN-D; ANTIGEN RATIO; MEN; DIAGNOSIS; MARKER; LEVEL; AGE;
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
This study aims to evaluate the role of free/total prostate-specific antigen (PSA) ratio, serum total sialic acid level and cathepsin D activity in the differentiation of prostate cancer and benign prostatic hyperplasia (BPH). The study looked at 100 patients with BPH, 75 patients with organ-confined or locally advanced prostate cancer, and a control group of 50 healthy volunteers. Prostate cancer patients showed significantly higher total sialic acid level and cathepsin D activity and lower free/total PSA ratio than those in the BPH group. The results suggest that combined measurement of serum total sialic acid and/or cathepsin D activity with free/total PSA ratio could serve as a useful adjunct to conventional diagnostics for the differentiation of prostate cancer and BPH.
引用
下载
收藏
页码：109 / 112
页数：4
相关论文
共 50 条
  • [31] The link between benign prostatic hyperplasia and prostate cancer
    David D. Ørsted
    Stig E. Bojesen
    Nature Reviews Urology, 2013, 10 : 49 - 54
  • [32] CANCER OF PROSTATE AMONG MEN WITH BENIGN PROSTATIC HYPERPLASIA
    GREENWALD, P
    KIRMSS, V
    POLAN, AK
    DICK, VS
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 53 (02): : 335 - 340
  • [33] Comparative pathology of benign prostatic hyperplasia and prostate cancer
    Maini, A
    Archer, C
    Wang, CY
    Haas, GP
    IN VIVO, 1997, 11 (04): : 293 - 299
  • [34] Urinary Biomarkers and Benign Prostatic Hyperplasia
    Pradeep Tyagi
    Zhou Wang
    Naoki Yoshimura
    Current Bladder Dysfunction Reports, 2019, 14 : 31 - 40
  • [35] Biomarkers for benign prostatic hyperplasia progression
    Cannon G.W.
    Getzenberg R.H.
    Current Urology Reports, 2008, 9 (4) : 279 - 283
  • [36] Urinary Biomarkers and Benign Prostatic Hyperplasia
    Tyagi, Pradeep
    Wang, Zhou
    Yoshimura, Naoki
    CURRENT BLADDER DYSFUNCTION REPORTS, 2019, 14 (02) : 31 - 40
  • [37] Biomarkers for the Diagnosis of Prostatic Inflammation in Benign Prostatic Hyperplasia
    Robert, Gregoire
    Smit, Frank
    Hessels, Daphne
    Jannink, Sander
    Karthaus, Herbert F. M.
    Aalders, Tilly
    Jansen, Kees
    de la Taille, Alexandre
    Mulders, Peter F.
    Schalken, Jack A.
    PROSTATE, 2011, 71 (15): : 1701 - 1709
  • [38] Men's theories about benign prostatic hyperplasia and prostate cancer following a benign prostatic hyperplasia decision aid
    Holmes-Rovner, M
    Price, C
    Rovner, DR
    Kelly-Bloke, K
    Lillie, J
    Wills, C
    Bonham, VL
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2006, 21 (01) : 56 - 60
  • [39] Men’s theories about benign prostatic hyperplasia and prostate cancer following a benign prostatic hyperplasia decision aid
    Margaret Holmes-Rovner
    Chrystal Price
    David R. Rovner
    Karen Kelly-Blake
    Janet Lillie
    Celia Wills
    Vence L. Bonham
    Journal of General Internal Medicine, 2006, 21 : 56 - 60
  • [40] IMAGING OF THE PROSTATE - BENIGN PROSTATIC HYPERPLASIA
    SCHECKOWITZ, EM
    RESNICK, MI
    UROLOGIC CLINICS OF NORTH AMERICA, 1995, 22 (02) : 321 - 332
12345